Advertisement

Influence of angiotensinogen M253T gene polymorphism and an angiotensin converting enzyme inhibitor on restenosis after percutaneous coronary intervention

      Abstract

      We studied the relation between renin-angiotensin system (RAS) related gene polymorphisms, such as angiotensin converting enzyme (ACE) insertion/deletion (I/D), angiotensinogen (AGT) M253T and angiotensin II type 1 receptor (AT1R) A1166C, and the effect of quinapril, an ACE inhibitor with high tissue-binding affinity, on preventing restenosis after percutaneous coronary intervention (PCI). A total of 253 patients successfully treated for coronary artery disease were randomly assigned to quinapril or control. Of the 215 patients who completed the follow-up, we determined gene polymorphisms in 204 patients with 241 lesions who provided blood samples for genotype determination. In the control, the ACE D homozygotes showed a smaller minimal lumen diameter (MLD) at follow-up (P=0.063). The other two genotypes of AGT and AT1R did not affect restenosis after PCI. According to quinapril treatment, the AGT T homozygotes significantly showed a beneficial effect of quinapril on MLD (P=0.013) and late lumen loss (P=0.013). The ACE I homozygotes also exhibited beneficial effects of quinapril on larger MLD (P=0.065). The AT1R genotype did not influence the quinapril effect. In conclusion, the AGT T homozygotes might benefit from effects of quinapril on preventing restenosis after PCI.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Landau C.
        • Lange R.A.
        • Hillis L.D.
        Percutaneous transluminal coronary angioplasty.
        New Engl. J. Med. 1994; 330: 981-993
        • Serruys P.W.
        • de Jaegere P.
        • Kiemeneij F.
        • Macaya C.
        • Rutsch W.
        • Heyndrickx G.
        • Emanuelsson H.
        • Marco J.
        • Legrand V.
        • Materne P.
        • et al.
        • For the Benestent Study Group
        A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease.
        New Engl. J. Med. 1994; 331: 489-495
        • Fischman D.L.
        • Leon M.B.
        • Baim D.S.
        • Schatz R.A.
        • Savage M.P.
        • Penn I.
        • Detre K.
        • Veltri L.
        • Ricci D.
        • Nobuyoshi M.
        • et al.
        For the Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease.
        New Engl. J. Med. 1994; 331: 496-501
        • Laporte S.
        • Escher E.
        Neointima formation after vascular injury is angiotensin II mediated.
        Biochem. Biophys. Res. Commun. 1992; 187: 1510-1516
        • Dzau V.J.
        Vascular renin-angiotensin system and vascular protection.
        J. Cardiovasc. Pharmacol. 1993; 22: S1-S9
        • Powell J.S.
        • Muller R.K.
        • Baumgartner H.R.
        Suppression of the vascular response to injury: the role of angiotensin- converting enzyme inhibitors.
        J. Am. Coll. Cardiol. 1991; 17: 137B-142B
        • Lam J.Y.
        • Lacoste L.
        • Bourassa M.G.
        Cilazapril and early atherosclerotic changes after balloon injury of porcine carotid arteries.
        Circulation. 1992; 85: 1542-1547
        • Lafont A.
        • Durand E.
        • Samuel J.L.
        • Besse B.
        • Addad F.
        • Levy B.I.
        • Desnos M.
        • Guerot C.
        • Boulanger C.M.
        Endothelial dysfunction and collagen accumulation: two independent factors for restenosis and constrictive remodeling after experimental angioplasty.
        Circulation. 1999; 100: 1109-1115
        • Mancini G.B.
        • Henry G.C.
        • Macaya C.
        • O'Neill B.J.
        • Pucillo A.L.
        • Carere R.G.
        • Wargovich T.J.
        • Mudra H.
        • Luscher T.F.
        • Klibaner M.I.
        • Haber H.E.
        • Uprichard A.C.
        • Pepine C.J.
        • Pitt B.
        • The TREND (Trial on Reversing ENdothelial Dysfunction) Study
        Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease.
        Circulation. 1996; 94: 258-265
        • Kiowski W.
        • Linder L.
        • Nuesch R.
        • Martina B.
        Effects of angiotensin converting enzyme inhibition on endothelial vasodilator function in primary human hypertension.
        Eur. Heart J. 1993; 14: 5-9
      1. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Circulation 1992;86:100–10.

        • Faxon D.P.
        • Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group
        Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double- blind, placebo-controlled trial of cilazapril.
        J. Am. Coll. Cardiol. 1995; 25: 362-369
        • Yamabe T.
        • Imazu M.
        • Yamamoto H.
        • Ueda H.
        • Hattori Y.
        • Hayashi Y.
        • Sekiguchi Y.
        • Ito M.
        • Yamakido M.
        Effect of cilazapril on vascular restenosis after percutaneous transluminal coronary angioplasty.
        Coron. Artery Dis. 1995; 6: 573-579
        • Okimoto T.
        • Imazu M.
        • Yamamoto H.
        • Sumii K.
        • Toyofuku M.
        • Kajiwara K.
        • Shimizu Y.
        • Yamakido M.
        Quinapril with high tissue affinity to tissue angiotensin converting enzyme inhibitor reduces restenosis after percutaneous transcatheter coronary revascularization.
        J. Am. Coll. Cardiol. 2000; 35 ([abstract]): 37A
        • Rigat B.
        • Hubert C.
        • Alhenc-Gelas F.
        • Cambien F.
        • Corvol P.
        • Soubrier F.
        An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.
        J. Clin. Invest. 1990; 86: 1343-1346
        • Jeunemaitre X.
        • Soubrier F.
        • Kotelevtsev Y.V.
        • Lifton R.P.
        • Williams C.S.
        • Charru A.
        • Hunt S.C.
        • Hopkins P.N.
        • Williams R.R.
        • Lalouel J.M.
        • et al.
        Molecular basis of human hypertension: role of angiotensinogen.
        Cell. 1992; 71: 169-180
        • Cambien F.
        • Poirier O.
        • Lecerf L.
        • Evans A.
        • Cambou J.P.
        • Arveiler D.
        • Luc G.
        • Bard J.M.
        • Bara L.
        • Ricard S.
        • et al.
        Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction.
        Nature. 1992; 359: 641-644
        • Caulfield M.
        • Lavender P.
        • Farrall M.
        • Munroe P.
        • Lawson M.
        • Turner P.
        • Clark A.J.
        Linkage of the angiotensinogen gene to essential hypertension.
        New Engl. J. Med. 1994; 330: 1629-1633
        • Iwai N.
        • Ohmichi N.
        • Nakamura Y.
        • Kinoshita M.
        DD genotype of the angiotensin-converting enzyme gene is a risk factor for left ventricular hypertrophy.
        Circulation. 1994; 90: 2622-2628
        • Hata A.
        • Namikawa C.
        • Sasaki M.
        • Sato K.
        • Nakamura T.
        • Tamura K.
        • Lalouel J.M.
        Angiotensinogen as a risk factor for essential hypertension in Japan.
        J. Clin. Invest. 1994; 93: 1285-1287
        • Hingorani A.D.
        • Jia H.
        • Stevens P.A.
        • Hopper R.
        • Dickerson J.E.
        • Brown M.J.
        Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition.
        J. Hypertens. 1995; 13: 1602-1609
        • Johnston C.I.
        • Mendelsohn F.A.
        • Cubela R.B.
        • Jackson B.
        • Kohzuki M.
        • Fabris B.
        Inhibition of angiotensin converting enzyme (ACE) in plasma and tissues: studies ex vivo after administration of ACE inhibitors.
        J. Hypertens. Suppl. 1988; 6: S17-S22
        • Anderson T.J.
        • Elstein E.
        • Haber H.
        • Charbonneau F.
        Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study).
        J. Am. Coll. Cardiol. 2000; 35: 60-66
        • Rigat B.
        • Hubert C.
        • Corvol P.
        • Soubrier F.
        PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1).
        Nucleic Acids Res. 1992; 20: 1433
        • Russ A.P.
        • Maerz W.
        • Ruzicka V.
        • Stein U.
        • Gross W.
        Rapid detection of the hypertension-associated Met235→Thr allele of the human angiotensinogen gene.
        Hum. Mol. Genet. 1993; 2: 609-610
        • Bonnardeaux A.
        • Davies E.
        • Jeunemaitre X.
        • Fery I.
        • Charru A.
        • Clauser E.
        • Tiret L.
        • Cambien F.
        • Corvol P.
        • Soubrier F.
        Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension.
        Hypertension. 1994; 24: 63-69
        • Ishigami T.
        • Umemura S.
        • Iwamoto T.
        • Tamura K.
        • Hibi K.
        • Yamaguchi S.
        • Nyuui N.
        • Kimura K.
        • Miyazaki N.
        • Ishii M.
        Molecular variant of angiotensinogen gene is associated with coronary atherosclerosis.
        Circulation. 1995; 91: 951-954
        • Nakauchi Y.
        • Suehiro T.
        • Yamamoto M.
        • Yasuoka N.
        • Arii K.
        • Kumon Y.
        • Hamashige N.
        • Hashimoto K.
        Significance of angiotensin I-converting enzyme and angiotensin II type 1 receptor gene polymorphisms as risk factors for coronary heart disease.
        Atherosclerosis. 1996; 125: 161-169
        • Dzau V.J.
        Cardiac renin-angiotensin system. Molecular and functional aspects.
        Am. J. Med. 1988; 84: 22-27
        • Rakugi H.
        • Kim D.K.
        • Krieger J.E.
        • Wang D.S.
        • Dzau V.J.
        • Pratt R.E.
        Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis.
        J. Clin. Invest. 1994; 93: 339-346
        • Ohishi M.
        • Ueda M.
        • Rakugi H.
        • Okamura A.
        • Naruko T.
        • Becker A.E.
        • Hiwada K.
        • Kamitani A.
        • Kamide K.
        • Higaki J.
        • Ogihara T.
        Upregulation of angiotensin-converting enzyme during the healing process after injury at the site of percutaneous transluminal coronary angioplasty in humans.
        Circulation. 1997; 96: 3328-3337
        • Rakugi H.
        • Wang D.S.
        • Dzau V.J.
        • Pratt R.E.
        Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation.
        Circulation. 1994; 90: 449-455
        • Ohishi M.
        • Fujii K.
        • Minamino T.
        • Higaki J.
        • Kamitani A.
        • Rakugi H.
        • Zhao Y.
        • Mikami H.
        • Miki T.
        • Ogihara T.
        A potent genetic risk factor for restenosis [letter].
        Nat. Genet. 1993; 5: 324-325
        • Samani N.J.
        • Martin D.S.
        • Brack M.
        • Cullen J.
        • Chauhan A.
        • Lodwick D.
        • Harley A.
        • Swales J.D.
        • de Bono D.P.
        • Gershlick A.H.
        Insertion/deletion polymorphism in the angiotensin-converting enzyme gene and risk of restenosis after coronary angioplasty.
        Lancet. 1995; 345: 1013-1016
        • Hamon M.
        • Amant C.
        • Bauters C.
        • Lablanche J.M.
        • Bertrand M.
        • Amouyel P.
        ACE polymorphism, a genetic predictor of occlusion after coronary angioplasty.
        Am. J. Cardiol. 1996; 78: 679-681
        • Amant C.
        • Bauters C.
        • Bodart J.C.
        • Lablanche J.M.
        • Grollier G.
        • Danchin N.
        • Hamon M.
        • Richard F.
        • Helbecque N.
        • McFadden E.P.
        • Amouyel P.
        • Bertrand M.E.
        D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting.
        Circulation. 1997; 96: 56-60
        • Koch W.
        • Kastrati A.
        • Mehilli J.
        • Bottiger C.
        • von Beckerath N.
        • Schomig A.
        Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is not associated with restenosis after coronary stent placement.
        Circulation. 2000; 102: 197-202
        • Katsuya T.
        • Koike G.
        • Yee T.W.
        • Sharpe N.
        • Jackson R.
        • Norton R.
        • Horiuchi M.
        • Pratt R.E.
        • Dzau V.J.
        • MacMahon S.
        Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease.
        Lancet. 1995; 345: 1600-1603
        • Winkelmann B.R.
        • Russ A.P.
        • Nauck M.
        • Klein B.
        • Bohm B.O.
        • Maier V.
        • Zotz R.
        • Matheis G.
        • Wolf A.
        • Wieland H.
        • Gross W.
        • Galton D.J.
        • Marz W.
        Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease.
        Am. Heart J. 1999; 137: 698-705
        • Okamura A.
        • Ohishi M.
        • Rakugi H.
        • Katsuya T.
        • Yanagitani Y.
        • Takiuchi S.
        • Taniyama Y.
        • Moriguchi K.
        • Ito H.
        • Higashino Y.
        • Fujii K.
        • Higaki J.
        • Ogihara T.
        Pharmacogenetic analysis of the effect of angiotensin-converting enzyme inhibitor on restenosis after percutaneous transluminal coronary angioplasty.
        Angiology. 1999; 50: 811-822